SIC
LOGC

Salem Investment Counselors’s LogicBio Therapeutics, Inc. Common Stock LOGC Stock Holding History

Salem Investment Counselors’s Portfolio LOGC Stock Details LOGC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-175
Closed – – 1159
2022
Q3 		$0 Hold
175
– – ﹤0.01% 1157
2022
Q2 		$0 Hold
175
– – ﹤0.01% 1153
2022
Q1 		$0 Hold
175
– – ﹤0.01% 1149
2021
Q4 		$0 Hold
175
– – ﹤0.01% 1133
2021
Q3 		$1K Hold
175
– – ﹤0.01% 957
2021
Q2 		$1K Buy
+175
New +$890 ﹤0.01% 886

Salem Investment Counselors's LOGC Position: Q4 2022 in Review

Salem Investment Counselors sold out of LogicBio Therapeutics, Inc. Common Stock (LOGC) in Q4 2022, closing a stake of 175 shares.

Salem Investment Counselors first reported a position in LOGC in Q2 2021 and held it in 6 quarters. The position peaked at $1K in Q3 2021. 0 funds tracked by Wall St. Rank hold LOGC as of Q4 2022.

  • Salem Investment Counselors reported no remaining LogicBio Therapeutics, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • Salem Investment Counselors sold 175 LogicBio Therapeutics, Inc. Common Stock shares in Q4 2022.
  • Salem Investment Counselors first reported a position in LogicBio Therapeutics, Inc. Common Stock in Q2 2021 and held it in 6 quarters.
  • Salem Investment Counselors's LogicBio Therapeutics, Inc. Common Stock position peaked at $1K in Q3 2021.
  • 0 funds tracked by Wall St. Rank held LogicBio Therapeutics, Inc. Common Stock as of Q4 2022.

Based on Salem Investment Counselors's 13F filing for Q4 2022, filed 15 Feb 2023.